Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Brayer, M. Fishman (2014)
Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.Journal of immunotherapy, 37 3
J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, Akihiko Ueda, M. Kanai, Y. Mori, S. Matsumoto, T. Murayama, S. Chikuma, S. Morita, M. Yokode, Akira Shimizu, T. Honjo, I. Konishi (2014)
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.Journal of Clinical Oncology, 32
Yu-fei He, Gui-mei Zhang, Xiao-hong Wang, Hui-fen Zhang, Ye Yuan, Dong Li, Zuo-hua Feng (2004)
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine1The Journal of Immunology, 173
G. Freeman, A. Long, Yoshiko Iwai, K. Bourque, T. Chernova, H. Nishimura, L. Fitz, Nelly Malenkovich, Taku Okazaki, M. Byrne, H. Horton, L. Fouser, L. Carter, V. Ling, M. Bowman, B. Carreno, M. Collins, C. Wood, T. Honjo (2000)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 192
K. Flaherty, I. Puzanov, Kevin Kim, A. Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard Lee, J. Grippo, K. Nolop, P. Chapman (2010)
Inhibition of mutated, activated BRAF in metastatic melanoma.The New England journal of medicine, 363 9
(2003)
effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C. Blank, I. Brown, A. Peterson, M. Spiotto, Yoshiko Iwai, T. Honjo, T. Gajewski (2004)
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 64
Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, Akira Mizoguchi, H. Hiai, N. Minato, Tasuku Honjo (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science, 291 5502
B. Blazar, B. Carreno, A. Panoskaltsis‐Mortari, L. Carter, Yoshiko Iwai, H. Yagita, H. Nishimura, P. Taylor (2003)
Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1The Journal of Immunology, 171
A. Ribas, F. Hodi, R. Kefford, O. Hamid, A. Daud, J. Wolchok, W. Hwu, T. Gangadhar, A. Patnaik, A. Joshua, P. Hersey, J. Weber, R. Dronca, H. Zarour, K. Gergich, Xiaoyun Li, R. Iannone, S. Kang, S. Ebbinghaus, C. Robert (2014)
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 18_suppl
R. Thompson, W. Webster, J. Cheville, C. Lohse, Haidong Dong, B. Leibovich, S. Kuntz, S. Sengupta, E. Kwon, M. Blute (2005)
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.Urology, 66 5 Suppl
S. Topalian, C. Drake, D. Pardoll (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.Current opinion in immunology, 24 2
(2014)
anti–PD-L1 antibody in patients with advanced cancer
(2014)
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients with melanoma
C. Jandus, G. Bioley, D. Speiser, P. Romero (2008)
Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral bloodCancer Immunology, Immunotherapy, 57
E. Garon, A. Balmanoukian, O. Hamid, R. Hui, L. Gandhi, N. Leighl, M. Gubens, J. Goldman, G. Lubiniecki, K. Emancipator, M. Dolled-Filhart, J. Lunceford, K. Gergich, N. Rizvi (2014)
Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.Clinical Cancer Research, 20
Hiroyuki Nishimura, M. Nose, H. Hiai, N. Minato, T. Honjo (1999)
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity, 11 2
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol (2013)
Nivolumab plus ipilimumab in advanced melanoma.The New England journal of medicine, 369 2
C. Lebbé, J. Weber, M. Maio, B. Neyns, K. Harmankaya, O. Hamid, S. O'Day, K. Chin, D. McDowell, L. Cykowski, B. McHenry, J. Wolchok (2013)
Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.Journal of Clinical Oncology, 31
F. Hirano, K. Kaneko, H. Tamura, Haidong Dong, Shengdian Wang, Masao Ichikawa, C. Rietz, D. Flies, J. Lau, G. Zhu, K. Tamada, Lieping Chen (2005)
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.Cancer research, 65 3
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.The New England journal of medicine, 366 26
S. Topalian, M. Sznol, D. McDermott, H. Kluger, R. Carvajal, W. Sharfman, J. Brahmer, D. Lawrence, M. Atkins, J. Powderly, P. Leming, E. Lipson, I. Puzanov, David Smith, J. Taube, J. Wigginton, G. Kollia, A. Gupta, D. Pardoll, J. Sosman, F. Hodi (2014)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
A. Amin, E. Plimack, J. Infante, M. Ernstoff, B. Rini, D. McDermott, J. Knox, S. Pal, M. Voss, P. Sharma, C. Kollmannsberger, D. Heng, J. Spratlin, Yun Shen, J. Kurland, P. Gagnier, H. Hammers (2014)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, 32
Fumihiko Tsushima, Kae Tanaka, N. Otsuki, Pornpan Youngnak, H. Iwai, K. Omura, M. Azuma (2006)
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma.Oral oncology, 42 3
J. Infante, B. Somer, Joon-Oh Park, Chung-Pin Li, M. Scheulen, Saifuddin Kasubhai, D. Oh, Yuan Liu, S. Lahiri, K. Steplewski, N. Le (2013)
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.Journal of Clinical Oncology, 31
(2013)
MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors
C. Blank, I. Brown, A. Peterson, M. Spiotto, Yoshiko Iwai, T. Honjo, T. Gajewski (2004)
PD-L 1 / B 7 H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor ( TCR ) Transgenic CD 8 T Cells
A. Meyer, G. Brabant, M. Behrend (2006)
Costimulatory Molecule B7-H1 in Primary and Metastatic Clear Cell Renal Cell Carcinoma
J. Taube, R. Anders, Geoffrey Young, Haiying Xu, Rajni Sharma, T. McMiller, Shuming Chen, A. Klein, D. Pardoll, S. Topalian, Lieping Chen (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 4
C. Garbe, K. Peris, A. Hauschild, P. Saiag, M. Middleton, A. Spatz, J. Grob, J. Malvehy, J. Newton-Bishop, A. Stratigos, H. Pehamberger, A. Eggermont (2010)
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.European journal of cancer, 46 2
D. Spigel, S. Gettinger, L. Horn, R. Herbst, L. Gandhi, M. Gordon, C. Cruz, P. Conkling, P. Cassier, S. Antonia, H. Burris, G. Fine, A. Mokatrin, M. Kowanetz, Xiao-dong Shen, Daniel Chen, J. Soria (2013)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 31
H. Nishimura, Tasuku Honjo (2001)
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.Trends in immunology, 22 5
M. Sznol, J. Powderly, David Smith, J. Brahmer, C. Drake, D. McDermott, D. Lawrence, J. Wolchok, S. Topalian, I. Lowy (2010)
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.Journal of Clinical Oncology, 28
D. Brusa, D. Massi, B. Merelli, M. Ciano, V. Audrito, S. Serra, G. Baroni, R. Nassini, D. Minocci, L. Cattaneo, A. Carobbio, S. Deaglio, M. Mandalà (2014)
Abstract 5604: PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressivenessCancer Research, 74
L. Carter, L. Fouser, J. Jussif, L. Fitz, Bija Deng, C. Wood, M. Collins, T. Honjo, G. Freeman, B. Carreno (2002)
PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2European Journal of Immunology, 32
(2013)
Safety, efficacy, and biomarkers of nivolumab with vaccine
(2010)
The PD-1/ PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target
O. Hamid, J. Sosman, D. Lawrence, R. Sullivan, N. Ibrahim, H. Kluger, P. Boasberg, K. Flaherty, P. Hwu, M. Ballinger, A. Mokatrin, M. Kowanetz, Daniel Chen, F. Hodi (2013)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).Journal of Clinical Oncology, 31
H. Kluger, M. Callahan, M. Postow, R. Gordon, N. Segal, N. Rizvi, A. Lesokhin, M. Atkins, J. Kirkwood, M. Burke, A. Ralabate, A. Rivera, S. Kronenberg, B. Agunwamba, W. Feely, Q. Hong, S. Krishnan, A. Gupta, J. Wolchok (2014)
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 18_suppl
F. Hodi, M. Sznol, H. Kluger, D. McDermott, R. Carvajal, D. Lawrence, S. Topalian, M. Atkins, J. Powderly, W. Sharfman, I. Puzanov, David Smith, P. Leming, E. Lipson, J. Taube, R. Anders, C. Horak, G. Kollia, A. Gupta, J. Sosman (2014)
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.Journal of Clinical Oncology, 32
D. Spigel, T. Ervin, R. Ramlau, D. Daniel, J. Goldschmidt, G. Blumenschein, M. Krzakowski, G. Robinet, B. Godbert, F. Barlesi, R. Govindan, T. Patel, S. Orlov, M. Wertheim, Wei Yu, J. Zha, R. Yauch, Premal Patel, S. Phan, A. Peterson (2013)
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 32
D. Schadendorf, F. Hodi, C. Robert, J. Weber, K. Margolin, O. Hamid, D. Patt, Tai-Tsang Chen, D. Berman, J. Wolchok (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
S. Spranger, R. Spaapen, Y. Zha, Jason Williams, Yuru Meng, T. Ha, T. Gajewski (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T CellsScience Translational Medicine, 5
M. Sznol, H. Kluger, F. Hodi, David McDermott, Richard Carvajal, Donald Lawrence, S. Topalian, M. Atkins, J. Powderly, W. Sharfman, I. Puzanov, David Smith, J. Wigginton, G. Kollia, A. Gupta, J. Sosman (2013)
Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 18_suppl
D. Benson, C. Bakan, A. Mishra, C. Hofmeister, Y. Efebera, B. Becknell, R. Baiocchi, Jianying Zhang, Jianhua Yu, Megan Smith, Carli Greenfield, P. Porcu, S. Devine, R. Rotem‐Yehudar, G. Lozanski, J. Byrd, M. Caligiuri (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.Blood, 116 13
A. Mellor, J. Sivakumar, P. Chandler, Kimberly Smith, H. Molina, D. Mao, D. Munn (2001)
Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancyNature Immunology, 2
T. Curiel, Shuang Wei, Haidong Dong, Xavier Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. Knutson, B. Daniel, M. Zimmermann, O. David, M. Burow, Alan Gordon, N. Dhurandhar, L. Myers, R. Berggren, A. Hemminki, R. Alvarez, D. Émilie, D. Curiel, Lieping Chen, W. Zou (2003)
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunityNature Medicine, 9
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine, 363 8
Yoshiko Iwai, S. Terawaki, T. Honjo (2004)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.International immunology, 17 2
Yuichiro Ohigashi, M. Sho, Yukishige Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane, Fumihiko Tsushima, N. Otsuki, H. Yagita, M. Azuma, Y. Nakajima (2005)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal CancerClinical Cancer Research, 11
(2010)
suppression by neutrophils
M. Amin, Ling Chen, Neeta Vachhajarani, E. Brunt, M. Doyle, B. Tan (2014)
Independent predictors of overall survival and recurrence in biphenotypic hepatocellular cancer.Journal of Clinical Oncology, 32
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
T. Curiel, G. Coukos, L. Zou, Xavier Alvarez, P. Cheng, P. Mottram, Melina Evdemon-Hogan, J. Conejo-Garcia, Lin Zhang, M. Burow, Yun Zhu, Shuang Wei, Ilona Kryczek, B. Daniel, Alan Gordon, L. Myers, A. Lackner, M. Disis, K. Knutson, Lieping Chen, W. Zou (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 10
J. Westin, F. Chu, M. Foglietta, R. Rotem‐Yehudar, S. Neelapu (2010)
Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma.Journal of Clinical Oncology, 28
R. Hino, K. Kabashima, Y. Kato, H. Yagi, Motonobu Nakamura, T. Honjo, Taku Okazaki, Y. Tokura (2010)
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 116
(2014)
death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma dependent mechanism
W. Fridman, F. Pagès, C. Sautès-Fridman, J. Galon (2012)
The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 12
D. Pardoll (2012)
The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 12
R. Thompson, Michael Gillett, J. Cheville, C. Lohse, Haidong Dong, W. Webster, K. Krejci, J. Lobo, S. Sengupta, Lieping Chen, H. Zincke, M. Blute, S. Strome, B. Leibovich, E. Kwon (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.Proceedings of the National Academy of Sciences of the United States of America, 101 49
S. Gettinger, F. Shepherd, S. Antonia, J. Brahmer, L. Chow, R. Juergens, H. Borghaei, Yun Shen, C. Harbison, S. Alaparthy, Allen Chen, N. Rizvi (2014)
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.Journal of Clinical Oncology, 32
J. Grosso, C. Horak, David Inzunza, Diana Cardona, J. Simon, A. Gupta, V. Sankar, Jong‐Soon Park, G. Kollia, J. Taube, R. Anders, M. Jure-Kunkel, J. Novotny, C. Taylor, Xiaoling Zhang, Therese Phillips, P. Simmons, J. Cogswell (2013)
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).Journal of Clinical Oncology, 31
J. Taube, A. Klein, J. Brahmer, Haiying Xu, Xiaoyu Pan, J. Kim, Lieping Chen, D. Pardoll, S. Topalian, R. Anders (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 20
S. Spranger, H. Koblish, B. Horton, P. Scherle, R. Newton, T. Gajewski (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironmentJournal for Immunotherapy of Cancer, 2
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, T. Honjo, N. Minato (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 99
R. Berger, R. Rotem‐Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, A. Nagler (2008)
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 14
Yan Zheng, Y. Zha, Grégory Driessens, F. Locke, T. Gajewski (2012)
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivoThe Journal of Experimental Medicine, 209
(2013)
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS
Nathan Bowers, E. Helton, R. Huijbregts, P. Goepfert, S. Heath, Z. Hel (2014)
Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 PathwayPLoS Pathogens, 10
J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus, W. Sharfman, E. Stankevich, A. Pons, Theresa Salay, T. McMiller, Marta Gilson, Changyu Wang, M. Selby, J. Taube, R. Anders, Lieping Chen, A. Korman, D. Pardoll, I. Lowy, S. Topalian (2010)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 19
S. Strome, Haidong Dong, H. Tamura, Stephen Voss, D. Flies, K. Tamada, D. Salomão, J. Cheville, F. Hirano, Wei Lin, J. Kasperbauer, K. Ballman, Lieping Chen (2003)
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.Cancer research, 63 19
A. Daud, O. Hamid, A. Ribas, F. Hodi, W. Hwu, R. Kefford, J. Wolchok, P. Hersey, J. Weber, R. Joseph, T. Gangadhar, R. Dronca, A. Patnaik, H. Zarour, A. Joshua, K. Gergich, Dianna Wu, J. Lunceford, K. Emancipator, M. Dolled-Filhart, N. Li, S. Ebbinghaus, S. Kang, C. Robert (2014)
Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcomeCancer Research, 74
O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu, R. Kefford, J. Wolchok, P. Hersey, R. Joseph, J. Weber, R. Dronca, T. Gangadhar, A. Patnaik, H. Zarour, A. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. Tumeh, B. Chmielowski, S. Ebbinghaus, Xiaoyun Li, S. Kang, A. Ribas (2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.The New England journal of medicine, 369 2
D. Gabrilovich, S. Nagaraj (2009)
Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 9
Haidong Dong, S. Strome, D. Salomão, H. Tamura, F. Hirano, D. Flies, P. Roche, Jun Lu, G. Zhu, K. Tamada, V. Lennon, E. Celis, Lieping Chen (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 8
(2012)
2012)The immune contexture in human tumours: impact on clinical outcome
J. Infante, J. Powderly, H. Burris, M. Kittaneh, J. Grice, J. Smothers, S. Brett, M. Fleming, Rena May, S. Marshall, M. Devenport, S. Pillemer, D. Pardoll, Lieping Chen, S. Langermann, P. LoRusso (2013)
Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.Journal of Clinical Oncology, 31
A. Salama, K. Flaherty (2013)
BRAF in Melanoma: Current Strategies and Future DirectionsClinical Cancer Research, 19
J. Weber, R. Kudchadkar, Bin Yu, Donna Gallenstein, C. Horak, H. Inzunza, Xiuhua Zhao, Alberto Martinez, Wenshi Wang, G. Gibney, J. Kroeger, Cabell Eysmans, A. Sarnaik, Y. Chen (2013)
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 34
Y. Latchman, C. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Yoshiko Iwai, A. Long, Julia Brown, Raquel Nunes, E. Greenfield, K. Bourque, V. Boussiotis, Laura Carter, B. Carreno, Nelly Malenkovich, H. Nishimura, Taku Okazaki, T. Honjo, A. Sharpe, G. Freeman (2001)
PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2
J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-akita, M. Nishimura (2004)
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 10
A. Salama, T. Chitnis, J. Imitola, M. Ansari, H. Akiba, Fumihiko Tushima, M. Azuma, H. Yagita, M. Sayegh, S. Khoury (2003)
Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune EncephalomyelitisThe Journal of Experimental Medicine, 198
Malignant melanoma is a significant public health problem; according to 2013 Surveillance, Epidemiology, and End Results data, its average incidence rate rose 2.6% each year for the last decade, and it is now the fifth most common cancer diagnosis in the United States. The rising incidence and historical poor response to chemotherapy have led to intense investigation of novel treatments for melanoma, including therapies to improve the immune-mediated destruction of cancer cells. Among the hallmarks of malignancy is the ability to evade this process: while early stages of tumor growth can induce functional CD8+ T-cell responses, cancer cells become increasingly embedded in an immune-suppressive tumor stroma. In the tumor microenvironment, T-cell proliferation and effector function are impaired due to engagement of T-cell programmed death receptor 1 (PD-1) with programmed death receptor ligand (PD-L1) expressed by cancer cells and antigen-presenting cells, which blocks T-cell-mediated cytotoxicity. This receptor-ligand engagement thereby inhibits immunity, allows the tumor to continue to grow, and contributes to the phenomenon of ‘T-cell exhaustion’. One immunotherapy strategy currently under investigation is inhibition of the interaction between PD-L1 and PD-1, thereby overcoming a critical immune checkpoint to facilitate destruction of cancer cells. In this review we discuss the preclinical rationale for PD-1 pathway inhibition in cancer, recent results of clinical trials targeting PD-1 and PD-L1, and evaluate its potential as a future anticancer therapy.
Therapeutic Advances in Medical Oncology – SAGE
Published: Sep 23, 2014
Keywords: immunotherapy,melanoma,programmed death receptor 1,programmed death receptor ligand
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.